Gapping up
In reaction to earnings/guidance: BBY +8.4%, QSII +8.1%, KZ +7.8%, TSL +6.4%, CRM +5.3%, NM +4.2%, WSM +4%, YOKU +3%, KIRK +3%, ACXM +2.9%, (also plans to sell IT Infrastructure Management Business), NGG +1.4%, EGHT +1.2%, .
M&A news: CTP +45.6% (agreed to exclusive negotiations to be acquired by DHR International; pricing and other terms not disclosed, but indicated preliminary price below the $7 per share DHR previously proposed), OCR +1.5% (to be acquired by CVS Health (CVS) for $98.00/share), .
Select pharma/biotech related names showing strength: AVEO +8.7%, ONCY +6.5%, CYCC +3.6%, CTIC +2.8%, GSK +1.8%, TKMR +1.8%, OSUR +1.7%, AZN +1.5%, SHPG +1.3%
Select oil/gas related names showing early strength: SDRL +2.1%, SDRL +2.1%, BP +1.4%, RDS.A +1.3%, STO +1.2%
Other news: AMPE +37.4% (announced positive results of its OptimEyes trial for DME), CALA +19.8% (reports positive initial Phase I safety data for CB-839, used to treat Acute Leukemias), PRAN +17.4% (announces the publication of minutes from the EMA regarding the previously announced Orphan Drug Designation for PBT2), ISR +17% (following ~100% move higher yesterday), ATNM +10.4% (following late move higher yesterday), MNGA +9.4% (announces that a major producer of painting systems viewed a MagneGas2 demo and has requested an immediate supply of the fuel for metal cutting), BLUE +8% (released abstract highlights including updated data for its Phase 1/2 HGB-205 study of LentiGlobin BB305), IPCI +7% (intends to accelerate its Rexista Oxycodone XR development program on the basis of positive feedback from the FDA), ACXM +2.9% (entered into an agreement to sell its IT Infrastructure Management business to Charlesbank Capital Partners and M/C Partners for total cash consideration of up to $190 mln; co also reported preliminary Q4 results), NBG +2.9% (cont vol surrounding Greece negotiations), QCOM +1.5% (announces an accelerated share repurchase agreement for $5 bln of its common stock, or ~57.7 mln shares), TTWO +1.3% (favorable commentary on Wednesday's Mad Money), REGN +0.9% (Regeneron Pharms and Sanofi (SNY) reports results from Phase 3 studies with Sarilumab in patients with Rheumatoid Arthritis met its co-primary efficacy endpoints)
Analyst comments: TNAV +3.8% ( initiated with a Outperform at Northland Capital; tgt $15), SSYS +3.3% (upgraded to Outperform at Oppenheimer), VOD +1.7% (upgraded to at ), ICPT +1.2% (initiated with an Overweight at Barclays; $425 tgt), BABA +1.1% (initiated with a Outperform at Bernstein)
In reaction to earnings/guidance: BBY +8.4%, QSII +8.1%, KZ +7.8%, TSL +6.4%, CRM +5.3%, NM +4.2%, WSM +4%, YOKU +3%, KIRK +3%, ACXM +2.9%, (also plans to sell IT Infrastructure Management Business), NGG +1.4%, EGHT +1.2%, .
M&A news: CTP +45.6% (agreed to exclusive negotiations to be acquired by DHR International; pricing and other terms not disclosed, but indicated preliminary price below the $7 per share DHR previously proposed), OCR +1.5% (to be acquired by CVS Health (CVS) for $98.00/share), .
Select pharma/biotech related names showing strength: AVEO +8.7%, ONCY +6.5%, CYCC +3.6%, CTIC +2.8%, GSK +1.8%, TKMR +1.8%, OSUR +1.7%, AZN +1.5%, SHPG +1.3%
Select oil/gas related names showing early strength: SDRL +2.1%, SDRL +2.1%, BP +1.4%, RDS.A +1.3%, STO +1.2%
Other news: AMPE +37.4% (announced positive results of its OptimEyes trial for DME), CALA +19.8% (reports positive initial Phase I safety data for CB-839, used to treat Acute Leukemias), PRAN +17.4% (announces the publication of minutes from the EMA regarding the previously announced Orphan Drug Designation for PBT2), ISR +17% (following ~100% move higher yesterday), ATNM +10.4% (following late move higher yesterday), MNGA +9.4% (announces that a major producer of painting systems viewed a MagneGas2 demo and has requested an immediate supply of the fuel for metal cutting), BLUE +8% (released abstract highlights including updated data for its Phase 1/2 HGB-205 study of LentiGlobin BB305), IPCI +7% (intends to accelerate its Rexista Oxycodone XR development program on the basis of positive feedback from the FDA), ACXM +2.9% (entered into an agreement to sell its IT Infrastructure Management business to Charlesbank Capital Partners and M/C Partners for total cash consideration of up to $190 mln; co also reported preliminary Q4 results), NBG +2.9% (cont vol surrounding Greece negotiations), QCOM +1.5% (announces an accelerated share repurchase agreement for $5 bln of its common stock, or ~57.7 mln shares), TTWO +1.3% (favorable commentary on Wednesday's Mad Money), REGN +0.9% (Regeneron Pharms and Sanofi (SNY) reports results from Phase 3 studies with Sarilumab in patients with Rheumatoid Arthritis met its co-primary efficacy endpoints)
Analyst comments: TNAV +3.8% ( initiated with a Outperform at Northland Capital; tgt $15), SSYS +3.3% (upgraded to Outperform at Oppenheimer), VOD +1.7% (upgraded to at ), ICPT +1.2% (initiated with an Overweight at Barclays; $425 tgt), BABA +1.1% (initiated with a Outperform at Bernstein)